Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

Jacob

IMMEL

Jacob is a native of Missouri. He received his B.S. in Chemistry from Southwest Baptist University where he performed research with Dr. Michael Harmata as a Steven’s Summer Research Fellow. Jacob joined the Bloom lab in 2018. His research involves the development of new methods for synthesizing peptide therapeutics with the goal of treating small cell lung cancer and HIV.

B.S. - 2018

Southwest Baptist University

Fun facts

  • Jacob hails from a small village of 65 people and hundreds of cattle.
  • He  enjoys playing sports, especially soccer in his free time.
current members
Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

INTERDISCIPLINARY SCIENCE BUILDING

1567 Irving Hill road
Lawrence, Kansas 66045

1-410-459-2135

email

Instagram Twitter Youtube Facebook

© 2020 The Bloom Group / All rights reserved 

Site by TriLion